Satsuma Pharma rises on latest data on migraine drug candidate

Satsuma Pharmaceuticals

20/12/2022 18:30

**  Satsuma Pharmaceuticals Inc's shares  STSA.O  up 11.1%
at 90 cents  
    ** Drug developer says further analysis of late-stage study
of its experimental drug to treat migraine showed clinically
sustained anti-migraine effects  urn:newsml:reuters.com:*:nGNX9Zkz1F
    ** Co's migraine drug candidate had failed to achieve
statistically significant result compared to placebo in a
late-stage study 
    ** Following the meeting with FDA in May, STSA says it's
confident regarding filing marketing application for the drug in
Q1 2023 based on the late-stage study data 
    ** STSA established manufacturing capability to support
marketing application, and seeks a commercialization partner 
    ** Including session gains, stock down ~80% YTD
 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))